Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Adenocarcinoma 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Metastatic Neuroendocrine Prostate Cancer 1Genital Neoplasms, Male 1Genital Diseases, Male 1Carcinoma, Transitional Cell 1Carcinoma, Lobular 1Biochemically Recurrent Prostate Carcinoma 1

Interventions

pembrolizumab 59Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 26Carboplatin 25Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × gallium 68 PSMA-11 × Clear all
NCT05562791 2026-04-22

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
20 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡